Christophe P Nicot, Ph.D.

Professor; Director, Center for Viral Oncology

Ph.D., University of Bordeaux, France, 1995
Research Associate, Case Western Reserve University, Dept. of Infectious Diseases, 1995-1996
Research Associate, Uniformed Services University of the Health Sciences, Dept of Microbiology and Immunology, 1996-1998
Visiting Fellow, National Cancer Institute, Division of Basic Sciences (DBS), 1998-2000
Professor, University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, 2009-present
Staff Scient. National Cancer Institute, DBS. 2000-2002
Assistant Professor, University of Kansas Medical Center, Department of Microbiology, Molecular genetics& Immunology, Kansas City, KS, 2003-2006
Associate Professor, University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, 2008-2009

Publications: Click here

The oncogenic human retrovirus HTLV-I is the etiological agent of an aggressive and fatal T-cell leukemia/lymphoma (ATL) disease. ATL is associated with a poor clinical prognosis and treatment of patients using conventional chemotherapy has limited benefit given that HTLV-I cells are resistant to conventional anti-cancer, apoptosis-inducing agents. In addition to ATLL, HTLV-I is also the etiological agent of an inflammatory neuro-degenerative disorder called Tropical Spastic Paraparesis/ HTLV-I-Associated Myelopathy (TSP/HAM). My laboratory studies early and late molecular events associated with cellular transformation and leukemogenesis. We are especially interested in genome instability, telomerase reactivation, RNA export and signaling pathways involved in T-cell transformation and/or virus replication. We also study new therapeutic approaches for treatment of ATL. Nicot Lab web site.

Selected Publications







  • Taylor JMNicot C. HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches. Apoptosis. 2008 Jun;13(6):733-47.
  • Bellon MNicot C. Central role of PI3K in transcriptional activation of hTERT in HTLV-I infected cells.Blood. 2008 May 29.
  • Bellon M, Nicot C. Regulation of telomerase and telomeres: human tumor viruses take control. J Natl Cancer Inst. 2008 Jan 16;100(2):98-108. Epub 2008 Jan 8.Open access.
  • Sinha-Datta U, Taylor JM, Brown M, Nicot C. Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis. 2008 Jan;13(1):33-40.Open access.


  • Bellon M, Nicot C. Telomerase: a crucial player in HTLV-I-induced human T-cell leukemia. : Cancer Genomics Proteomics. 2007 Jan-Feb;4(1):21-5. Open access.
  • Datta A, Nicot C. Telomere attrition induces a DNA double-strand break damage signal that reactivates p53 transcription in HTLV-I leukemic cells. Oncogene. 2007 Aug 20. Open access.
  • Lacoste V, Nicot C, Gessain A, Valensi F, Gabarre J, Matta H, Chaudhary PM, Mahieux R. In primary effusion lymphoma cells, MYB transcriptional repression is associated with v-FLIP expression during latent KSHV infection while both v-FLIP and v-GPCR become involved during the lytic cycle. Br J Haematol. 2007 Aug;138(4):487-501. Open access
  • Sinha-Datta U, Datta A, Ghorbel S, Dodon MD, Nicot C. Human T-cell lymphotrophic virus type I rex and p30 interactions govern the switch between virus latency and replication. J Biol Chem. 2007 May 11;282(19):14608-15. Open access
  • Brown M, Bellon M, Nicot C. Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood. 2007 Feb 15;109(4):1653-9. Open access
  • Fukumoto R, Dundr M, Nicot C, Adams A, Valeri VW, Samelson LE, Franchini G. Inhibition of TCR Signal Transduction and Viral Expression by the Linker for Activation of T Cells-Interacting p12I Protein of HTLV-1.  J Virol. 2007 Jun 20. Open access


  • Ghorbel S, Sinha-Datta U, Dundr M, Brown M, Franchini G, Nicot C. Human T-cell leukemia virus type I p30 nuclear/nucleolar retention is mediated through interactions with RNA and a constituent of the 60 S ribosomal subunit.  J Biol Chem. 2006 Dec 1;281(48):37150-8. Open access
  • Bellon M, Datta A, Brown M, Pouliquen JF, Couppie P, Kazanji M, Nicot C. Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia.  Int J Cancer. 2006 Nov 1;119(9):2090-7. Open access
  • Datta A, Sinha-Datta U, Dhillon NK, Buch S, Nicot C. The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti- inflammatory cytokines from human macrophages.  J Biol Chem. 2006 Aug 18;281(33):23414-24.Open access
  • Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent 
    senescence. Blood. 2006 Aug 1;108(3):1021-9. Epub 2006 Mar 28. Open access


  • Nicot C, Harrod RL, Ciminale V, Franchini G.
    Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. Oncogene. 2005 Sep 5;24(39):6026-34. Open access
  • Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol. 2005 Mar;78(3):232-9. Open access


  • Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princler GL, Derse D, Misteli T, Franchini G.
    HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med. 2004 Feb;10(2):197-201. Open access
  • Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot JC, Brown M, Kazanji M, Barrett JC, Nicot C.
    Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood. 2004 Oct 15;104(8):2523-31. Open access


Last modified: Mar 07, 2016


Christophe P Nicot, Ph.D.
Professor; Director, Center for Viral Oncology

Pathology & Laboratory Medicine
3901 Rainbow Blvd
Kansas City, KS 66160

P: 913-588-6724/ Lab:913-588-7050